Here are five insights:
1. End users’ increasing interest in spine biologics is boosting the market.
2. The growing geriatric population and increasing number of spinal disorder cases will also spur market growth.
3. The demand for minimally invasive procedures is helping market expansion.
4. Potential complications with spine surgery present a market barrier.
5. Medtronic, Johnson & Johnson, Stryker, NuVasive and Zimmer Biomet reflect dominant market players.
More articles on biologics:
Stanford creates gel for neural stem cell regeneration: 6 things to know
Xtant Medical, curasan enter distribution agreement: 5 things to know
SeaSpine launches OsteoStrand Demineralized Bone Fibers for spinal surgery, 1st procedures performed: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.